Teleflex Inc is a leading global provider of medical technologies designed to enhance the health and well-being of patients. With a diverse product portfolio, the company specializes in the development, manufacturing, and distribution of innovative medical devices for a wide range of applications. Teleflex focuses on delivering high-quality solutions in critical care, surgical care, urology, and respiratory care, among others. By leveraging its expertise and strong market presence, Teleflex continuously aims to improve patient outcomes, increase healthcare efficiency, and advance medical innovation.

Teleflex Inc is primarily active in a variety of industries. As a global provider of medical technology products, the company focuses on healthcare, providing innovative solutions in the areas of surgical and diagnostic devices, anesthesia, and critical care. Teleflex Inc also has a presence in the aerospace industry, supplying specialized control systems and components for aircraft and helicopters. With its diverse portfolio, Teleflex Inc continues to make significant contributions in these sectors, driving advancements and improving patient outcomes in healthcare, while delivering reliable and efficient solutions in the aerospace industry.

The main competitors of Teleflex Inc in the market include Johnson & Johnson, Becton, Dickinson and Company, Medtronic plc, and Smiths Medical.

Teleflex Inc is a renowned company specializing in medical technology. Established in 1943, Teleflex has a rich history rooted in innovation and industry leadership. With headquarters in Wayne, Pennsylvania, the company has expanded globally, offering a diverse portfolio of medical devices that enhance patient care and improve clinical outcomes. Teleflex's dedication to research and development has led to breakthrough solutions in respiratory care, surgical instruments, urology, vascular access, and more. By combining cutting-edge technology with a commitment to quality, Teleflex continues to shape the healthcare industry, providing healthcare professionals with the tools they need to deliver superior patient care.

Teleflex Inc has achieved several significant milestones throughout its history. The company expanded its product portfolio by acquiring Arrow International in 2007, a leading manufacturer of critical care products. In 2011, Teleflex successfully launched the MANTA Vascular Closure Device, revolutionizing the way vascular access sites are closed after procedures. Additionally, the company received FDA clearance for the Teleflex UroLift System in 2013, providing a minimally invasive solution for enlarged prostate patients. In recent years, Teleflex also made significant advancements in its vascular access product line, including the introduction of the ARROW PICC with Chlorag+ard Technology. These achievements highlight Teleflex's continuous commitment to innovation and improving patient outcomes.

Teleflex Inc is primarily present in various countries and regions worldwide. The company has a strong global presence, with operations in North America, Europe, Asia Pacific, and Latin America. Teleflex serves customers and healthcare markets in over 150 countries, providing innovative solutions in medical technology and consumer healthcare. With its diverse portfolio of products and services, Teleflex Inc has established itself as a trusted provider in the medical device industry.

Teleflex Inc represents a set of core values and a corporate philosophy that guide its operations. With a focus on innovation and excellence, the company strives to deliver high-quality medical technology solutions to enhance patient outcomes. Teleflex is committed to providing world-class customer service, ensuring the best user experience for healthcare professionals and patients. With a dedication to integrity, teamwork, and continuous improvement, Teleflex values collaboration, transparency, and ethical conduct in all aspects of its business. By prioritizing customer needs and embracing a culture of innovation, Teleflex aims to make a positive impact in the healthcare industry.

Analysts currently set an average price target of 137,93 USD for the Teleflex stock (median: 131,58 USD), implying +6,0 % versus the latest price. The consensus is based on 18 analyst ratings.

Teleflex Analyytikkojen kursstavoitteet 2026

18 analysts currently rate the Teleflex stock: 5 recommend buying, 12 holding and 1 selling. For 2026, analysts expect Teleflex to generate revenue of 3,69 Mrd. USD and earnings per share of 14,49 USD.

Teleflex Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Teleflex share trades at 113,68 EUR (130,16 USD).

The Teleflex share (TFX) is listed on 6 stock exchanges, including: NYSE (TFX), XETRA (TBH.DE), Frankfurt (TBH.F), München (TBH.MU), Düsseldorf (TBH.DU), SIX (Zürich) (TBH.SW).

Teleflex Inc. is an American company specializing in the manufacturing and selling of medical devices and instruments. It was founded in 1943 and has become a leading provider of medical products. The company divides its business into three main segments: Medical Devices, Anesthesia, and Interventional Medicine. Each segment offers a wide range of products tailored to the specific needs of the healthcare industry. The Medical Devices segment focuses on catheters, leads, drains, and other surgical instruments, while also offering specialized products for cardiology, oncology, and neurology. The Anesthesia segment specializes in products used in anesthesia applications, such as ventilation support devices and block needles. The Interventional Medicine segment focuses on treating and preventing vascular diseases with products like vascular access devices and balloon catheters used in minimally invasive procedures. This segment is the fastest-growing for Teleflex due to increasing demand for minimally invasive treatment methods. Teleflex has built a portfolio of over 30,000 products through acquisitions and internal innovations. Effective management, partnerships with doctors and hospitals, and participation in industry events ensure the company's growth and expansion. In summary, Teleflex Inc. is a company with a wide range of medical products used in various sectors of the healthcare industry. With a global presence and diverse product portfolio, the company can respond to changing customer desires and needs. Through continuous innovation, research, and development, Teleflex aims to revolutionize the healthcare industry and achieve higher levels of effectiveness and efficiency.

odotettu liikevaihto Teleflex on 3,69 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Teleflex on 682,34 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Teleflex:n hinta-voitto-suhde (P/E) on tällä hetkellä 8,98. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Teleflex-osakkeen arvostusta.

Teleflex:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,66. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Teleflex-osakkeen arvostuskennuslukuna.

Teleflex:n Eulpool-laatuscore on 5/10.

Teleflex:n ISIN on US8793691069. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Teleflex:n WKN on 855853. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Teleflex:n ticker on TFX. Tämä pörssinoteeraus käytetään Teleflex-osakkeiden kauppaan pörssissä.

Viimeisten 12 kuukauden aikana Teleflex maksoi osinkoa 1,36 USD . Tämä vastaa osingontuottoa noin 1,04 %. Tulevien 12 kuukauden aikana Teleflex odotetaan maksavan osinkoa 1,36 USD.

Teleflex:n nykyinen osinkotuotto on 1,04 %.

Teleflex maksaa osinkoa, joka jaetaan kuukausina , , , .

Teleflex maksoi osinkoa joka vuosi viimeisten 36 vuoden aikana.

Tulevien 12 kuukauden aikana odotetaan osinkoja, joiden määrä on 1,36 USD. Tämä vastaa osingontuottoa 1,04 %.

Teleflex kuuluu sektoriin 'Terveydenhuolto'.

Vuonna 2025 Teleflex jakoi 1,36 USD osinkona.

Teleflex:n osingot jaetaan valuutassa USD.